Mendoza TLA, Osorio RMÁ, Henao RCM, Arias GMD, Mendoza TLI

Language: Spanish
References: 30
Page: 408-416
PDF size: 255.45 Kb.

ABSTRACT

Background: Neonatal sepsis causes significant morbidity and neonatal mortality and antibiotic resistance now a day is a public health problem. Objective: To determine the antimicrobial susceptibility patterns and assess antibiotic regimens used in non-nosocomial bacterial infections in the neonatal ICU Foundation Hospital San Jose de Buga, Colombia, between 2006-2011. Patients and methods: A descriptive study evaluated the bacterial susceptible to empirical antibiotic scheme, employing Stata ^® 11.0 for analysis. Results: We included 100 infants and 100 isolates. Among Gram (+) the best susceptibility was for cefazolin (88.9%;95%CI:65.3-98.6%) and Gram (-) amikacin (94.1%;95%CI:85.6-98.4%) and cefepime (89.1%;95%CI:80.6-97.5%). For all bacteria, ampicillin-amikacin schemes (93.8%; 95%CI:86-97.9%) and cefazolin-amikacin (85.1;95%CI:76.4-93.9%) were the best performance. Conclusions: The empirical schemes currently employed, are far from ideal. New schemes should be evaluated as ampicillin-amikacin and cefazolin-amikacin non-meningeal bacterial infections, keeping ampicillin-cefotaxime for meningitis.

REFERENCES

1. Modi N, Doré CJ, Saraswatula A, Ricahrds M, Bamford KB, Coello R, et al. A case definition for national and international neonatal bloodstream infection surveillance. Arch Dis Child Fetal Neonatal Ed. 2009; 94: F8-12.

2. Stoll BJ, Holman RC and Schuchat A. Decline in sepsisassociated neonatal and infant deaths in the United States, 1979 through 1994. Pediatrics. 1998; 102: e18.

3. Stoll BJ, Gordon T, Korones SB, Shankaran S, Tyson JE, Bauer C, et al. Early-onset sepsis in very low birth weight neonates: A report from the National Institute of Child Health and Human Development Neonatal Research Network. J Pediatr. 1996; 129: 72-80. Grupo bacteriano Gram Negativos Oxacilina – Gentamicina Susceptibilidad % (IC 95%) Oxacilina – Amikacina Susceptibilidad % (IC 95%) Cefazolina – Gentamicina Susceptibilidad % (IC 95%) Cefazolina – Amikacina Susceptibilidad % (IC 95%) Escherichia s n: 37 67,5 (51,1-84) 97,1 (85,1-99,9) 91,4 (76,9-98,2) 100 (90-100) Klebsiella sp. n: 16 87,5 (61,7-98,4) 93,7 (69,8-99,8) 87,5 (61,7-98,4) 93,7 (69,8-99,8) Enterobacter sp. n: 8 75 (34,9-96,8) 87,5 (47,3-99,7) 100 (59-100) 100 (63,1-100) Serratia sp. n: 4 25 (0,6-80.6) 100 (39,7-100) 25 (0,6-80.6) 100 (39,8-100) Otros Gram Negativos n: 5 60 (14,7-94,7) 80 (28,4-99,5) 60 (14,7-94,7) 80 (28,4-99,5) Gram Positivos Streptococcus sp. n: 10 100 (66,4-100) 10 (69,2-100) 100 (59-100) 100 (63,1-100) Staphilococcus aureus n: 5 60 (14,7-94,7) 60 (14,7-94,7) 80 (28,4-99,5) 80 (28,4-99,5) Staphilococcus coagulasa 100 100 100 Negativo n: 1 100 100 100 100 Otros Gram Positivos n: 6 66,6 (22,3-95,7) 66,6 (22,3-95,7) 80 (28,4-99,5) 80 (28,4-99,5) Tabla 4. Patrón de susceptibilidad antimicrobiana bacterias. Esquemas antibióticos. 416 Revista de Enfermedades Infecciosas en Pediatría

4. Stoll BJ, Gordon T, Korones SB, Shankaran S, Tyson JE, Bauer C, et al. Late-onset sepsis in very low birth weight neonates: A report from the National Institute of Child Health and Human Development Neonatal Research Network. J Pediatr. 1996; 129: 63-71.

5. Stoll BJ, Hansen N, Fanaroff AA, Wright LL, Carlo WA, Ehrenkranz RA, et al. Late onset sepsis in very low birth weight neonates: the experience of the NICHD Neonatal Research Network. Pediatrics. 2002; 110: 285-291.

6. Kilbride HW, Wirtschafter DD, Powers RJ and Sheenan MB. Implementation of evidence based potentially better practices to decrease nosocomial infections. Pediatrics. 2003; 111: 519-533.

7. Stoll BJ, Hansen NI, Higgins RD, Fanaroff AA, Duara S, Goldberg R, et al. Very low birth weight preterm infants with early onset neonatal sepsis: the predominance of gram-negative infections continues in the National Institute of Child Health and Human Development Neonatal Research Network, 2002-2003. Pediatr Infect Dis J. 2005; 24(7): 635-639.

8. Lopez-Sastre JB, Fernandez CB, Coto GD and Ramos AA. Trends in the epidemiology of neonatal sepsis of vertical transmission in the era of group B streptococcal prevention. Acta Paediatr. 2005; 94(4): 451-457.

9. Berger A, Witt A, Haiden N, Kretzer V, Heinze G and Pollak A. Amniotic cavity cultures, blood cultures, and surface swabs in preterm infants--useful tools for the management of early-onset sepsis?. J Perinat Med. 2004; 32(5): 446-452.

10. Jardine L, Davies MW and Faoagali J. Incubation time required for neonatal blood cultures to become positive. J Paediatr Child Health. 2006; 42(12): 797-802.

11. Stelling J and O’Brien T. Surveillance of antimicrobial resistance: The WHONET Program. Clin Infect Dis. 1997; 19(24) (Supl.1): 157-168.

12. O’Brien T, Stelling J. WHONET: Removing obstacles to the full use of information about antimicrobial resistance. Diagn Microbiol Infect Dis. 1996; 25: 163-168.

13. Fernández F, López J, Ponce LM y Machado C. Resistencia Bacteriana. Revista Cubana Médico Militar. 2003; 32(1): 44-8.

14. Hart CA. La resistencia a los antibióticos. ¿Un problema creciente? Br Med J (Ed Latinoam). 1998; 6: 147-8.

15. Lay M. Bacterial resistance in the 90s. Contemp Pediatr. 1994; 11(4): 72-99.

16. Davies J. Inactivation of Antibiotics and the Dissemination of Resistance Genes. Science. 1994; 264(5157): 375-382.

17. Bizzarro MJ, Raskind C, Baltimore RS, Gallagher PG. Seventy- five years of neonatal sepsis at Yale: 1928-2003. Pediatrics. 2005; 116: 595-602.

18. Vesikari T, Janas M, Grönroos P, Tuppurainen N, Renlund M, Kero P, Koivisto M, Kunnas M, Heinonen K, Nyman R, Pettay O, Osterlund K. Neonatal septicaemia. Arch Dis Child. 1985; 60: 542-6.

19. Butler KM, Baker CJ. Candida: an increasingly important pathogen in the nursery. Pediatr Clin North Am. 1988; 35: 543-63.

20. Rangel-Frausto MS, Wiblin T, Blumberg HM, Saiman L, Patterson J, Rinaldi M, et al. National epidemiology of mycoses survey (NEMIS): variations in rates of bloodstream infections due to Candida species in seven surgical intensive care units and six neonatal intensive care units. Clin Infect Dis. 1999; 29: 253-8.

21. Fridkin SK, Kaufman D, Edwards JR, Shetty S, Horan T. Changing incidence of Candida bloodstream infections among NICU patients in the United States: 1995-2004. Pediatrics. 2006; 117: 1680-7.

22. Shim GH, Kim SD, Kim HS, Kim ES, Lee HJ, Lee JA, et al. Trends in Epidemiology of Neonatal Sepsis in a Tertiary Center in Korea: A 26-Year Longitudinal Analysis, 1980- 2005. J Korean Med Sci. 2011; 26: 284-289.

23. Osrin D, Vergnano S and Costello A. Serious bacterial infections in newborn infants in developing countries. Curr Opin Infect Dis. 2004; 17: 217-224.

24. Tapia JL, Reichhard C, Saldías MI, Abarzúa F, Pérez ME, González A, et al. Sepsis neonatal en la era de profilaxis antimicrobiana prenatal. Rev Chil Infect. 2007; 24(2): 111-116.

25. Muller-Pebody B, Johnson AP, Health PT, Gilbert RE, Henderson KL and Sharland M. Empirical treatment of neonatal sepsis: are the current guidelines adequate? Arch Dis Child Fetal Neonatal. 2011; 96: F4-F8.

26. Stoll BJ, Hansen NI, Sánchez PJ, Faix RG, Poindexter BB, Krisa P, et al. Sepsis neonatal de inicio temprano Análisis del impacto del estreptococo grupo B y E. Coli en la sepsis neonatal temprana. Pediatrics. 2011; 127: 817-826.

27. Torres C. Lectura interpretada del antibiograma de cocos grampositivos. Enferm Infecc Microbiol Clin. 2002; 20(7): 354-64.

28. Navarro F, Miró E y Mirelis B. Lectura interpretada del antibiograma de enterobacterias. Enferm Infecc Microbiol Clin. 2002; 20(5): 225-34.

29. Kayange N, Kamugisha E, Mwizamholya DL, Jeremiah S, and Mshana SE. Predictors of positive blood culture and deaths among neonates with suspected neonatal sepsis in a tertiary hospital, Mwanza- Tanzania. BMC Pediatrics. 2010; 10: 39. Disponible en: http://www.biomedcentral. com/1471-2431/10/39/prepub

30. Mendoza LA y Arias MG. Susceptibilidad antimicrobiana en una Unidad de Cuidados Intensivos Neonatales: experiencia de 43 meses. Revista de Enfermedades Infecciosas en Pediatría. 2009; 23(93): 13-24.